A Critical Chiral Building Block for Peptide Therapeutics and Neurological Drug Discovery: Boc-D-Serine Methyl Ester (CAS 95715-85-8)

Boc-D-Serine methyl ester (N-(tert-Butoxycarbonyl)-D-serine methyl ester, Boc-D-Ser-OMe, CAS: 95715-85-8) is a high-purity, chirally defined amino acid derivative with the molecular formula C₉H₁₇NO₅ and a molecular weight of 219.24 g/mol. Its structure features a reactive methyl ester-protected carboxylic group and a tert-butyloxycarbonyl (Boc) group that reversibly blocks the amine functionality, ensuring selective, orthogonal deprotection under mild acidic conditions. This unique combination of orthogonal protection and chirality—the unnatural D‑amino acid stereochemistry (D‑serine, the “mirror image” of the natural L‑serine)—is precisely what makes Boc-D-Ser-OMe an indispensable and high-value building block. As the most widely applied protected form of D‑serine, Boc-D-Ser-OMe plays a pivotal role across multiple high-value sectors: it serves as a critical monomer in solid‑phase peptide synthesis (SPPS) for the efficient incorporation of D‑serine residues into peptide chains; it is an essential intermediate in the development of peptidomimetic drugs and neurologically active compounds, exemplified by its use as a primary synthetic precursor for the anticonvulsant drug Lacosamide (Vimpat) and its analogs; it acts as a reference standard for chiral purity analysis; and it is the direct starting material for the synthesis of the D‑serine methyl ester hydrochloride (D-Ser-OMe·HCl) free base, after simple Boc deprotection. Boc-D-Ser-OMe can be readily converted to the D‑amino ester hydrochloride or further derivatized to more complex chiral intermediates. The compound is typically supplied as a white to off‑white crystalline powder with a purity range of 97‑99% by HPLC, meeting ≥98.0% (HPLC) specifications, and is stored at 2‑8°C under an inert atmosphere to ensure long‑term stability.

In the global peptide therapeutics industry—which was estimated at USD 739.1 million in 2024 and is projected to reach USD 1.6 billion by 2032, growing at an exceptional 10.1% CAGR—D-amino acids are not minor additives but are essential structural elements¶ Incorporating D‑enantiomers into peptide backbones (as opposed to standard L‑monomers) dramatically enhances resistance to enzymatic proteolysis (increasing plasma half‑life several fold), blocks unwanted aggregation, and allows access to novel secondary structures not available to all‑L peptides, thereby generating improved drug candidates. Boc-D-Serine methyl ester directly addresses this fundamental demand by providing the D‑configuration serine residue in a fully protected, SPPS‑ready form.

The global D‑serine derivative market, valued at approximately USD 65 million in 2024, is projected to reach USD 115 million by 2033 at a CAGR of 6.5%, reflecting the rising adoption of D-amino acids in next‑generation peptide therapeutics. The distinct chirality of Boc-D-Ser-OMe—the D‑enantiomer rather than the natural L‑form—confers metabolic stability and resistance to proteolytic degradation, properties that are critical for the development of peptide drugs with extended in‑vivo half‑lives. As a result, the compound is experiencing growing demand from pharmaceutical research and development pipelines.

The global market for Boc-D-serine methyl ester is moderately fragmented but with a clear leadership structure in which major international suppliers—including TCI (Japan), Thermo Fisher Scientific (USA), Santa Cruz Biotechnology (USA), Chem-Impex (USA), BOC Sciences (USA), Creative Peptides (USA), ChemScene (USA), and European distributors—occupy most of the developed‑market share for high‑purity (>98%) research and cGMP grades. Chinese manufacturers have rapidly expanded their capacities for essential protected amino acid building blocks and are now fully integrated into global peptide synthesis supply chains, offering industrial‑scale production volumes at competitive pricing. As a specialized supplier of fine chemical intermediates, Shanghai XinChem Co., Ltd. (XinChem) has established a fully integrated, quality‑controlled supply chain for high‑purity Boc-D-Serine methyl ester (Boc-D-Ser-OMe) for the global peptide synthesis, pharmaceutical research, and chiral chemical manufacturing industries. Our product is manufactured under strict quality management, achieving consistent purity (≥98‑99% by HPLC), white to off‑white crystalline powder form, low residual solvents, and low heavy metals. It is available with USP residual solvents and ICH Q3D heavy metal qualification, and is fully compatible with both standard Fmoc/t‑Bu SPPS methods using DMF/NMP cleavage cocktails and with Boc/Bzl SPPS strategies. XinChem is ideally positioned to meet the growing global demand from peptide API manufacturers, CROs, and research institutions.

Core Application Fields

Boc-D-serine methyl ester’s orthogonal protection scheme and D‑enantiomer chirality drive concentrated demand across four major sectors:

• Peptide (Proteinogenic) & Peptidomimetic Synthesis (≈45% of product demand by mass): Serves as a core SPPS monomer for controlled introduction of D‑serine residues. It is a key synthetic precursor for unnatural amino acid incorporation and peptide backbone engineering, including the synthesis of the anticonvulsant drug Lacosamide (Vimpat) and its structural analogs. The unusual D‑serine configuration confers high resistance to proteases (increasing plasma half‑life), stabilization of β‑turn and helix conformations, and improved target selectivity.
• Neurological & CNS Drug Discovery (≈25%): An advanced intermediate and chirality source for small‑molecule drugs and peptide therapeutics targeting neurological disorders—including epilepsy (Lacosamide derivatives), schizophrenia via D‑serine/NMDA receptor modulation, and other CNS applications.
• Biochemical Research & Chiral Chemistry (≈20%): An essential chiral auxiliary for asymmetric synthesis, a reference standard in chiral HPLC method development, and a precursor for unnatural D‑amino acid containing bio‑conjugates.
• Pharmaceutical Reference & Analytical Standards (≈10%): A calibration and validation standard for quantifying D‑serine and its metabolites in cerebrospinal fluid (CSF), plasma, and tissue homogenates.

Regional Market Dynamics

Global demand for Boc-D-serine methyl ester shows distinct regional leadership: United States & Canada (≈35‑40% of global end user demand) dominate high‑value, high‑purity (>99%) peptide synthesis and neurological drug discovery consumption, driven by the world’s largest biopharmaceutical R&D pipeline, major academic research funding (NIH), and the highest density of peptide API and CRO CDMO facilities. Europe (≈30‑35%) follows as a major consumer, especially Germany, Switzerland, and the UK, with strict regulatory requirements (REACH, EMA) and concentrated expertise in CNS drug discovery. Asia‑Pacific (≈20‑25%) is the fastest‑growing region (CAGR 7‑9%), led by China (dominant manufacturing hub) and India, and powered by government biotech initiatives (China’s “Made in China 2025”), rapidly expanding CRO CDMO capacity, and increasing domestic peptide API and small‑molecule pharmaceutical demand. Rest of the world (Latin America, Middle East & Africa) remains a nascent but emerging market, with most demand satisfied by imports from Asian suppliers.

Penetrating these markets requires:

• For US/Canada: USP/NF compliance, FDA‑auditable cGMP quality systems, DMF support, and cold‑chain integrity for costly cGMP campaigns.
• For EU: REACH registration, compliance with EMA peptide‑API guideline documentation, and full traceability to biocidal/bioactive principles.
• For Asia‑Pacific: Scaling from research grams to multi‑kilogram production quantities, ISO manufacturing compliance, and competitively priced, impurity‑certified material.

Regulatory and Environmental Considerations

Boc-D-serine methyl ester is not classified as a hazardous substance or mixture under EU Regulation (EC) No. 1272/2008 (CLP) and is not considered dangerous under Directive 67/548/EEC. Safe handling requires avoidance of dust formation, use of adequate ventilation or local exhaust, and storage at 2‑8°C, refrigerated, under inert atmosphere (nitrogen recommended) in tightly sealed containers away from moisture, light, and oxidizing agents. The material is stable for at least 24‑36 months when stored under proper, validated stability storage conditions. In the EU, Boc-D-serine methyl ester may be subject to the REACH Regulation (EC 1907/2006) as a chemical substance; however, as a laboratory reagent and building block for peptide synthesis rather than a large‑volume industrial substance sold >1,000 metric tons/year, many small‑volume manufacturers are exempt from full registration if annual tonnage thresholds are not met, but importers and producers must nevertheless provide Safety Data Sheets (SDS). In the US, Boc-D-serine methyl ester is regulated under the Toxic Substances Control Act (TSCA) as a research chemical. Handling and storage must comply with OSHA workplace exposure standards for combustible and particulate‑forming solids. The compound is classified as a combustible solid; transport is regulated under DOT/IMDG/IATA as non‑hazardous for most small‑volume shipments but may require special classification for bulk industrial quantities. Environmentally, Boc-D-serine methyl ester is expected to be readily biodegradable (OECD 301 series), with low aquatic toxicity and no anticipated bioaccumulation. Manufacturing generates limited solvent‑containing waste streams and requires responsible disposal of spent solvents. Chem‑enzymatic manufacturing routes that reduce total solvent consumption and energy use are emerging.

Future Outlook

The global market outlook for Boc-D-serine methyl ester is tied to, and will directly benefit from, four powerful macro‑sectoral drivers:

1. The global peptide therapeutics market explosion: Peptide synthesis market value is projected to grow from USD 739.1 million in 2024 to USD 1.6 billion by 2032 at a 10.1% CAGR, and the D‑amino acid derivative segment is growing at 6.5% CAGR. Boc-D-Ser-OMe competes exclusively in the D‑building block segment, directly capturing a share of this growth.
2. Neurological drug discovery and CNS clinical pipelines: Novel D‑serine‑based therapeutics for NMDA receptor modulation in schizophrenia, stroke, neurodegeneration, and epilepsy (Lacosamide) continue to enter clinical trials; Boc-D-Ser-OMe is the direct synthetic precursor for the first‑line drug Lacosamide and its next‑generation analogs.
3. Asia‑Pacific and Indian CRO/CDMO expansion: Asian manufacturers dominate cost‑effective, multi‑kilogram synthesis of Boc-D-Ser-OMe, positioning them to capture market share as small‑molecule API manufacturers turn to Asian CROs for custom peptide manufacturing.
4. Chirality and resistance to biological enzymes: Incorporation of D‑amino acids into peptide backbones is the only effective chemical strategy to block protease susceptibility and extend therapeutic peptide half‑life in vivo while preserving or enhancing biological activity. The increasing regulatory preference for long‑acting (hence protease‑resistant) peptide drugs (especially GLP‑1 analogs and antimicrobial peptides) will directly drive Boc-amino acid demand.

Looking ahead, chemical suppliers must focus on providing validated cGMP quality and regulatory documentation (DMF, COA) for late‑stage and commercial peptide API production, building cold‑chain integrity into global logistics (2‑8°C), maintaining consistent industrial‑scale capacities (multi‑hundred kilogram to metric ton levels), and developing impurity profiling and analytical method validation to meet increasingly rigorous ICH Q3A, Q3B, Q3C, and Q3D standards.

Shanghai XinChem Co. Ltd.

As a specialized supplier of fine chemical intermediates, Shanghai XinChem Co., Ltd. (XinChem) has established a fully integrated, quality‑controlled supply chain for high‑purity Boc-D-Serine methyl ester (Boc-D-Ser-OMe, CAS 95715-85-8) for the global peptide synthesis, pharmaceutical research, and chiral chemical manufacturing industries.

1. Technical Advantages

• High Purity & Orthogonal Protection: Our Boc-D-Ser-OMe achieves purity ≥98‑99% by HPLC, with Boc-amine protection stable to mild base (piperidine in DMF) and mild acid (TFA/DCM, 5‑20%) cleavable orthogonal to C‑terminal methyl ester (removed by saponification). Typical specifications: white to off‑white crystalline powder, chiral purity (HPLC area%) ≥98.5%, melting point 46‑48°C, density 1.08 g/mL (25°C), refractive index n²⁰/D 1.453, molecular weight 219.24 g/mol, molecular formula C₉H₁₇NO₅.
• Low Impurity Profile: Full characterization by HPLC, LC‑MS, and chiral HPLC; residual solvents meet USP/ICH Class 3 limits; heavy metals (Pb, As, Cd, Hg) ≤10 ppm by ICP‑MS (ICH Q3D).
• Batch‑to‑Batch Consistency: Critical quality attributes—purity, optical rotation, chiral purity—controlled within 0.5%, ≤0.5%, ≤0.5% relative standard deviation.

2. Product Advantages

• Versatile D‑Serine Chiral Pharmacophore: Direct SPPS monomer for D‑serine introduction (Fmoc/t‑Bu or Boc/Bzl), direct precursor for D-Ser-OMe·HCl free base via mild TFA cleavage (retaining chirality), and building block for Lacosamide anticonvulsants, peptidomimetic therapeutics, and unnatural amino acid synthesis.
• Superior Chemical Stability: Stable for >24 months when stored as supplied (2‑8°C, inert atmosphere, tightly sealed, away from moisture). Non‑hygroscopic, crystalline material simplifies handling and long‑term archiving of reference standards.
• Flexible Packaging Options: 5g, 10g, 25g, 50g, 100g, 500g glass/HDPE (R&D); 1kg HDPE (pilot); 5kg, 10kg, 25kg fiber drums and full custom packaging for industrial scales.
• Cold‑Chain & Just‑in‑Time Delivery: Refrigerated warehousing (2‑8°C, nitrogen blanket, humidity‑controlled), qualified thermal shippers, logistics solutions for global life science customers.

3. Key Application Industries & Sub‑Sectors

• Peptide Therapeutics & Drug Discovery: SPPS for D‑serine‑containing peptides, peptidomimetics, neuroactive peptides, GPCR peptide modulators, cyclic peptide scaffolds, and unnatural amino acid libraries.
• Neurological & CNS APIs: Primary synthetic precursor for Lacosamide (Vimpat), anticonvulsant drug discovery, NMDA receptor glycine‑site modulators, and D‑serine–based neurological compounds.
• Chiral Pharmaceutical Intermediates: Building block for diverse D‑amino ester derivatives (by ester exchange), chiral auxiliaries for asymmetric synthesis, and peptidomimetic drug candidate construction.
• Biochemical Research: Reference standard for chiral HPLC method validation, D‑serine metabolic pathway analysis (kynurenine pathway, neuroinflammation), and NMDA receptor agonist/antagonist development.

4. Service Support

XinChem’s experienced technical team provides impurity profiling, chiral purity and method validation, regulatory documentation (DMF support for pharmaceutical customers, COA, TDS, MSDS, REACH, TSCA), custom packaging, custom synthesis of analog derivatives (e.g., D-Ser-OMe·HCl free base, methyl ester analogs), cold‑chain logistics, and just‑in‑time delivery.

5. Why Choose XinChem

• Professionalism: 20+ years in the chiral chemical, pharmaceutical, life‑science, and peptide synthesis industries.
• Flexibility: Tailored to individual customer purity requirements, chiral specifications, custom packaging, and validated global cold‑chain delivery logistics.
• Cost‑effectiveness: High purity and investment‑grade quality at competitive, industrial‑scale pricing.

Contact us now to start cooperation!

Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532